Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020August 16, 2022 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

2020

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum

March 15, 2022August 16, 2022

PLoS ONE Journal Publishes Mechanistic Model of Alzheimer’s Disease Endorsing Prana’s PBT2

July 17, 2013August 16, 2022

Prana’s Parkinson’s drug meets Michael J. Fox Foundation development milestone – PBT434 advances through IND enabling studies

July 17, 2013August 16, 2022

Recent Posts

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065